Coya Therapeutics 的收益超出预期，但其股价下跌;分析师仍然建议买入。 Coya Therapeutics beat earnings estimates, but its stock fell; analysts still recommend buying.

科亚治疗公司是一家生物技术公司,开发治疗方法以调节监管T细胞,它报告季度收入为EPS(0.26美元),超过分析师的预期(0.41美元)。 Coya Therapeutics, a biotech firm developing treatments to modulate regulatory T cells, reported quarterly earnings of ($0.26) EPS, surpassing analyst expectations of ($0.41). 尽管估计超过了预期, 但周五股价略跌至7.21美元. Despite beating estimates, the stock dipped slightly to $7.21 on Friday. 来自Chardan Capital和HC Wainwright的分析师都发布了“买入”评级,目标价格分别为14.00美元和18.00美元。 Analysts from Chardan Capital and HC Wainwright have both issued "buy" ratings with target prices of $14.00 and $18.00, respectively.

文章

The Enterprise Leader

WKRB 13

Markets Daily

-- 显示更少 --

延伸阅读

相关故事